AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Celularity Inc. raises over $10 million in an initial financing closing as part of a $28 million recapitalization to accelerate growth.
PUBLIC · CELUSep 24, 2026
Amount Raised
$10 Million
Round Type
Venture
Florham ParkBiotechnology
Description
Celularity Inc. announced an initial closing generating over $10 million from a private placement of senior secured convertible notes and warrants. This closing is part of a broader plan to raise up to $25 million in new capital. The financing follows significant operating improvements, including a substantial reduction in monthly cash burn
Company Information
Company
Celularity
Location
170 Park Avenue
Florham Park, New Jersey, United States
About
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.
Fundz sees it the moment Celularity raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.